Neurogene Inc. Increase (Decrease) in Accounts Payable and Other Operating Liabilities
Neurogene Inc. (NGNE) reported Increase (Decrease) in Accounts Payable and Other Operating Liabilities of $2.26 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-20.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities · last filed 2023-03-20
- Neurogene Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2020-03-31 was $568.00K.
- Neurogene Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2019-12-31 was $1.97M.
- Neurogene Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2019-09-30 was -$181.00K.
- Neurogene Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2019-06-30 was -$2.50M, a 163.08% decline year-over-year.
- Neurogene Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2022 was $2.26M.
- Neurogene Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2021 was -$142.00K, a 104.71% decline from fiscal 2020.
- Neurogene Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2020 was $3.02M.
- Neurogene Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2019 was -$2.01M.
| Period end | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 3 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 6 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 9 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 12 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $2.26M 10-K · filed 2023-03-20 | ||||
| 2021-12-31 | -$142.00K 10-K · filed 2023-03-20 | ||||
| 2020-12-31 | $3.02M 10-K · filed 2022-03-01 | ||||
| 2020-03-31 | $568.00K 10-Q · filed 2020-05-06 | $2.53M derived: sum of 2 quarters · filed 2021-03-25 | $2.35M derived: sum of 3 quarters · filed 2021-03-25 | -$142.00K derived: sum of 4 quarters · filed 2021-03-25 | |
| 2019-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.78M derived: sum of 2 quarters · filed 2021-03-25 | -$710.00K derived: sum of 3 quarters · filed 2021-03-25 | -$2.01M 10-K · filed 2021-03-25 | -$2.24M 10-K · filed 2020-03-12 |
| 2019-09-30 | -$181.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | -$2.68M derived: sum of 2 quarters · filed 2019-11-13 | -$3.97M 10-Q · filed 2019-11-13 | -$10.13M derived: sum of 4 quarters · filed 2020-05-06 | |
| 2019-06-30 | -$2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$3.79M 10-Q · filed 2019-08-01 | -$9.95M derived: sum of 3 quarters · filed 2020-05-06 | -$12.59M derived: sum of 4 quarters · filed 2020-05-06 | |
| 2019-03-31 | -$1.30M 10-Q · filed 2020-05-06 | -$7.46M derived: sum of 2 quarters · filed 2020-05-06 | -$10.09M derived: sum of 3 quarters · filed 2020-05-06 | -$6.14M derived: sum of 4 quarters · filed 2020-05-06 | |
| 2018-12-31 | -$6.16M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$8.80M derived: sum of 2 quarters · filed 2020-03-12 | -$4.84M derived: sum of 3 quarters · filed 2020-03-12 | -$6.47M 10-K · filed 2020-03-12 | |
| 2018-09-30 | -$2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $1.32M derived: sum of 2 quarters · filed 2019-11-13 | -$313.00K 10-Q · filed 2019-11-13 | $3.61M derived: sum of 4 quarters · filed 2020-03-12 | |
| 2018-06-30 | $3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $2.32M 10-Q · filed 2019-08-01 | $6.25M derived: sum of 3 quarters · filed 2020-03-12 | $5.12M derived: sum of 4 quarters · filed 2020-03-12 | |
| 2018-03-31 | -$1.63M 10-Q · filed 2019-05-07 | $2.29M derived: sum of 2 quarters · filed 2020-03-12 | $1.16M derived: sum of 3 quarters · filed 2020-03-12 | $3.51M derived: sum of 4 quarters · filed 2020-03-12 | |
| 2017-12-31 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $2.79M derived: sum of 2 quarters · filed 2020-03-12 | $5.14M derived: sum of 3 quarters · filed 2020-03-12 | $1.82M 10-K · filed 2020-03-12 | |
| 2017-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $1.21M derived: sum of 2 quarters · filed 2018-11-07 | -$2.10M 10-Q · filed 2018-11-07 | -$728.00K derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-06-30 | $2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$973.00K 10-Q · filed 2018-08-08 | $402.00K derived: sum of 3 quarters · filed 2019-03-07 | $137.00K derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-03-31 | -$3.31M 10-Q · filed 2018-05-08 | -$1.94M derived: sum of 2 quarters · filed 2019-03-07 | -$2.21M derived: sum of 3 quarters · filed 2019-03-07 | $610.00K derived: sum of 4 quarters · filed 2019-03-07 | |
| 2016-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $1.11M derived: sum of 2 quarters · filed 2019-03-07 | $3.92M derived: sum of 3 quarters · filed 2019-03-07 | $4.82M 10-K · filed 2019-03-07 | |
| 2016-09-30 | -$265.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $2.55M derived: sum of 2 quarters · filed 2017-11-08 | $3.44M 10-Q · filed 2017-11-08 | $4.50M derived: sum of 4 quarters · filed 2018-03-12 | |
| 2016-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $3.71M 10-Q · filed 2017-08-08 | $4.77M derived: sum of 3 quarters · filed 2018-03-12 | $4.49M derived: sum of 4 quarters · filed 2018-03-12 | |
| 2016-03-31 | $890.00K 10-Q · filed 2017-05-09 | $1.96M derived: sum of 2 quarters · filed 2018-03-12 | $1.67M derived: sum of 3 quarters · filed 2018-03-12 | $671.00K derived: sum of 4 quarters · filed 2018-03-12 | |
| 2015-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $782.00K derived: sum of 2 quarters · filed 2018-03-12 | -$219.00K derived: sum of 3 quarters · filed 2018-03-12 | -$450.00K 10-K · filed 2018-03-12 | |
| 2015-09-30 | -$283.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$1.28M derived: sum of 2 quarters · filed 2016-11-09 | -$1.51M 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | -$1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$1.23M 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | -$231.00K 10-Q · filed 2016-05-10 | ||||
| 2014-12-31 | $3.61M 10-K · filed 2017-03-09 | ||||
| 2013-12-31 | $1.18M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |